Ken Griffin Ayala Pharmaceuticals, Inc. Call Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AYLA
# of Institutions
1Shares Held
0Call Options Held
0Put Options Held
0About Ayala Pharmaceuticals, Inc.
- Ticker AYLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,833,300
- Description
- Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinic...